The nonthyroidal illness syndrome
非甲状腺疾病综合征
基本信息
- 批准号:7537207
- 负责人:
- 金额:$ 32.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-07-01 至 2012-06-30
- 项目状态:已结题
- 来源:
- 关键词:AccountingAcetylationAcuteAddressAdenovirusesAnimalsCell Culture TechniquesCellsChronic DiseaseDefectDevelopmentEndotoxinsEnzymesEuthyroid Sick SyndromesGene DeletionGenesGenetic TranscriptionHepatocyteHumanHypothalamic DiseasesIodothyronine DeiodinaseKnockout MiceLigandsLigationLipopolysaccharidesMedicalMethylationModelingMusOperative Surgical ProceduresOutcomePhosphorylationPost-Translational Protein ProcessingPuncture procedureRecoveryRoleSepsisSerumSeveritiesSeverity of illnessSyndromeTestingThyroid Hormone ReceptorThyroxineTriiodothyronineTriiodothyronine Receptorsbasecytokineimprovedin vivoiodothyronine deiodinase type Imortalitymouse modelnuclear receptor coactivator 1pituitary thyroid axispreventpromoterresponse
项目摘要
DESCRIPTION (provided by applicant): The nonthyroidal illness syndrome (NTIS), also called the sick euthyroid syndrome, is the state of a low serum thyroid hormone (T3) concentration associated with any acute or chronic illness, without intrinsic disease of the hypothalamic-pituitary-thyroid axis. The severity of the NTIS correlates directly with the severity of illness, and multiple studies show that the severity of the NTIS is an independent and powerful predictor of mortality. The long term objectives of these studies are to understand the mechanisms underlying the NTIS and to address whether it should ever be treated, and if so, what the treatment should be. The first Specific Aim will use cell culture and in vivo mouse models to address the mechanisms underlying the decreased conversion of thyroxine to T3 that characterizes the NTIS. The activity and expression of type 1 iodothyronine deiodinase (D1) are known to be decreased by illness. This effect is due at least in part to a defective ability of thyroid hormone receptors to induce transcription of the D1 gene, Dio1. The relationship between defective D1 expression, the low serum T3, and thyroid hormone receptor coactivator function will be investigated. Specific Aim 2 will use two in vivo mouse models of NTIS, endotoxin administration and sepsis, to test whether a specific therapy (forced expression of a thyroid hormone receptor coactivator) can ameliorate the NTIS and decrease mortality rate. Specific Aim 3 will evaluate the basis for impaired thyroid hormone receptor coactivator function in the NTIS. Cytokine or illness-associated potential mechanisms to be explored include induction of corepressors that compete with the coactivators, redistribution of coactivators to other genes, redistribution of coactivators to other regions of the cell, and abnormalities in post-translational modifications of coactivators. The severity of the nonthyroidal illness syndrome (NTIS) correlates directly with the severity of illness, and multiple studies show that the severity of the NTIS is an independent and powerful predictor of mortality. These studies will address whether treatment of the NTIS improves recovery from serious medical illnesses.
描述(由申请人提供):非甲状腺疾病综合征(NTIS),也称为病态甲状腺功能正常综合征,是与任何急性或慢性疾病相关的低血清甲状腺激素(T3)浓度状态,没有下丘脑-垂体-甲状腺轴的内在疾病。NTIS的严重程度与疾病的严重程度直接相关,多项研究表明,NTIS的严重程度是死亡率的一个独立而有力的预测指标。这些研究的长期目标是了解NTIS的潜在机制,并确定是否应该治疗,如果应该治疗,应该采用什么治疗方法。第一个特异性目标将使用细胞培养和体内小鼠模型来解决NTIS特征甲状腺素向T3转化减少的机制。已知1型碘甲状腺原氨酸脱碘酶(D1)的活性和表达会因疾病而降低。这种影响至少部分是由于甲状腺激素受体诱导D1基因Dio1转录的能力有缺陷。探讨D1表达缺陷、低血清T3与甲状腺激素受体辅激活因子功能之间的关系。特异性目标2将使用两种体内NTIS小鼠模型,内毒素给药和败血症,来测试特异性治疗(强制表达甲状腺激素受体共激活因子)是否可以改善NTIS并降低死亡率。特异性目标3将评估NTIS中甲状腺激素受体辅助激活因子功能受损的基础。有待探索的细胞因子或疾病相关的潜在机制包括诱导与共激活因子竞争的共抑制因子、共激活因子再分配到其他基因、共激活因子再分配到细胞的其他区域,以及共激活因子翻译后修饰的异常。非甲状腺疾病综合征(NTIS)的严重程度与疾病的严重程度直接相关,多项研究表明NTIS的严重程度是死亡率的一个独立而有力的预测因子。这些研究将探讨NTIS的治疗是否能改善严重疾病的康复。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RONALD Jay KOENIG其他文献
RONALD Jay KOENIG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RONALD Jay KOENIG', 18)}}的其他基金
In vivo therapy and mechanisms of PAX8-PPARgamma thyroid cancer
PAX8-PPARγ甲状腺癌的体内治疗及机制
- 批准号:
9036341 - 财政年份:2013
- 资助金额:
$ 32.3万 - 项目类别:
In vivo therapy and mechanisms of PAX8-PPARgamma thyroid cancer
PAX8-PPARγ甲状腺癌的体内治疗及机制
- 批准号:
8628804 - 财政年份:2013
- 资助金额:
$ 32.3万 - 项目类别:
In vivo therapy and mechanisms of PAX8-PPARgamma thyroid cancer
PAX8-PPARγ甲状腺癌的体内治疗及机制
- 批准号:
8451143 - 财政年份:2013
- 资助金额:
$ 32.3万 - 项目类别:
Pax8-PPARgamma regulation of transcription and metabolism in thyroid cancer
Pax8-PPARgamma 对甲状腺癌转录和代谢的调节
- 批准号:
8683123 - 财政年份:2010
- 资助金额:
$ 32.3万 - 项目类别:
Pax8-PPARgamma regulation of transcription and metabolism in thyroid cancer
Pax8-PPARgamma 对甲状腺癌转录和代谢的调节
- 批准号:
8118802 - 财政年份:2010
- 资助金额:
$ 32.3万 - 项目类别:
Pax8-PPARgamma regulation of transcription and metabolism in thyroid cancer
Pax8-PPARgamma 对甲状腺癌转录和代谢的调节
- 批准号:
8504792 - 财政年份:2010
- 资助金额:
$ 32.3万 - 项目类别:
Retinoic acid and regulation of BMP4 in development
视黄酸和 BMP4 发育中的调节
- 批准号:
7082160 - 财政年份:2003
- 资助金额:
$ 32.3万 - 项目类别:
相似海外基金
Investigating the functions of histone acetylation in genome organization and leukemogenesis
研究组蛋白乙酰化在基因组组织和白血病发生中的功能
- 批准号:
EP/Y000331/1 - 财政年份:2023
- 资助金额:
$ 32.3万 - 项目类别:
Research Grant
Gene Modulation of Acetylation Modifiers to Reveal Regulatory Links to Human Cardiac Electromechanics
乙酰化修饰剂的基因调节揭示与人类心脏机电的调节联系
- 批准号:
10677295 - 财政年份:2023
- 资助金额:
$ 32.3万 - 项目类别:
Novel roles of PDK2 in heart failure: Regulation of mitochondrial nuclear crosstalk via metabolic regulation and histone acetylation
PDK2 在心力衰竭中的新作用:通过代谢调节和组蛋白乙酰化调节线粒体核串扰
- 批准号:
10635599 - 财政年份:2023
- 资助金额:
$ 32.3万 - 项目类别:
Regulation of hepatic lysine N-acetylation by cysteine proximity due to alcohol toxicity
酒精毒性导致的半胱氨酸接近对肝脏赖氨酸 N-乙酰化的调节
- 批准号:
10752320 - 财政年份:2023
- 资助金额:
$ 32.3万 - 项目类别:
Histone Acetylation Regulates Microglial Innate Immune Memory
组蛋白乙酰化调节小胶质细胞先天免疫记忆
- 批准号:
478927 - 财政年份:2023
- 资助金额:
$ 32.3万 - 项目类别:
Operating Grants
Dysregulation of Histone Acetylation in Parkinson's Disease
帕金森病中组蛋白乙酰化的失调
- 批准号:
10855703 - 财政年份:2023
- 资助金额:
$ 32.3万 - 项目类别:
Obesity-related hypertension: the contribution of PPAR gamma acetylation and asprosin
肥胖相关高血压:PPAR γ 乙酰化和白脂素的贡献
- 批准号:
10654210 - 财政年份:2023
- 资助金额:
$ 32.3万 - 项目类别:
The role N-terminal acetylation in dilated cardiomyopathy and associated arrhythmia
N-末端乙酰化在扩张型心肌病和相关心律失常中的作用
- 批准号:
10733915 - 财政年份:2023
- 资助金额:
$ 32.3万 - 项目类别:
In vivo tracing of hepatic ethanol metabolism to histone acetylation: role of ACSS2 in alcohol-induced liver injury
肝脏乙醇代谢与组蛋白乙酰化的体内追踪:ACSS2 在酒精性肝损伤中的作用
- 批准号:
10667952 - 财政年份:2023
- 资助金额:
$ 32.3万 - 项目类别:
The function of TWIST1 acetylation in cell fate and tissue development
TWIST1 乙酰化在细胞命运和组织发育中的作用
- 批准号:
10726986 - 财政年份:2023
- 资助金额:
$ 32.3万 - 项目类别: